Results 221 to 230 of about 2,229,234 (312)

[Guideline, acute lymphoblastic leukemia].

open access: yes[Rinsho ketsueki] The Japanese journal of clinical hematology, 2013
openaire   +2 more sources

Beyond the Document: A Single‐Center Qualitative Study of Survivorship Care Plan Barriers and Opportunities Across Pediatric Oncology Stakeholders

open access: yesPediatric Blood &Cancer, Volume 73, Issue 11, November 2026.
ABSTRACT Background Survivorship care plans (SCPs) summarize cancer treatment and guide risk‐based follow‐up for cancer survivors, yet remain difficult to create, share, and use. Stakeholder perspectives are needed to inform usable approaches.
Molly S. Talman   +4 more
wiley   +1 more source

Mapping the de-implementation of traditional diagnostic tests in pediatric acute lymphoblastic leukemia. [PDF]

open access: yesFront Oncol
Salek M   +8 more
europepmc   +1 more source

Differential expression of cancer‐related genes supports prediction of poor response to first‐line treatments in T‐ALL pediatric patients with high minimal residual disease

open access: yesMolecular Oncology, Volume 20, Issue 11, Page 2637-2646, November 2026.
In the present work, we have identified a transcriptional signature based on the differential expression of six genes (BCL2&MAST4, HSH2D&LAT2, METRN&PITPNM2) that would facilitate the early detection of T‐cell acute lymphoblastic leukemia (T‐ALL) patients prone to a poor treatment response and could be implemented at diagnosis, along with other risk ...
Antonio Lahera   +11 more
wiley   +1 more source

Navigating Asparaginase Treatment for Patients With Acute Lymphoblastic Leukemia: US Consensus Panel Recommendations on the Role of Multidisciplinary Care

open access: yesAmerican Journal of Hematology, Volume 101, Issue 11, Page 2713-2725, November 2026.
ABSTRACT Asparaginase is a critical treatment component for patients with acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL). However, the successful delivery of asparaginase‐based therapy remains challenging across care settings due to its complex administration, distinct toxicity profile, prolonged treatment duration, and the need for ...
Amir Ali   +8 more
wiley   +1 more source

Opportunities and Challenges in FLASH Radiotherapy: Focusing on Normal Tissue Protection Effects and Clinical Translation Bottleneck

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT FLASH radiotherapy (FLASH‐RT) has garnered significant attention for its “FLASH effect”, which selectively protects normal tissues while maintaining tumor‐killing efficacy at ultra‐high dose rates (UHDR). This technology represents a promising but still investigational therapeutic strategy in radiation oncology.
Xuan‐Lu He   +10 more
wiley   +1 more source

Pharmacogenomics in Cancer Treatment: Challenges and Opportunities in African Settings

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Background Cancer incidence in Africa is projected to reach 2.1 million new cases annually by 2040. Current treatment guidelines remain largely based on pharmacogenomic data predominantly from European and Asian genetic profiles, potentially compromising safety and efficacy in African patients.
Ntombikhona Fortunate Maphumulo   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy